The brokerage has reduced its valuation multiple to 0.8x (from 0.9x) on decline in FY24E ROE due to increase in equity base on one-off gain...

Piramal Enterprises, incorporated in the year 1947, is a Large Cap company (having a market cap of Rs 19954.67 Crore) operating in Diversif...

Piramal Enterprises, incorporated in the year 1947, is a Large Cap company (having a market cap of Rs 21390.23 Crore) operating in Diversif...

Stressing that maintaining a strong focus on quality and compliance is another important area of growing significance in the pharma sector,...

The broader NSE Nifty too inched closer to the key 11,500 mark.

The marriage, due in December, of the scions of two big business families has the undertones of a royal wedding in the making.

According to Bloomberg Billionaire index, Maran was India’s 21st richest individual as on date.

Captains of top industrial houses will converge in Mohali on Wednesday to commit investments in Punjab.

The construction work for the proposed 718-metre skyscraper had started after it had got approvals from the civic authority in 2010.

The company will be looking at countries like Indonesia, Vietnam, Sri Lanka, Myanmar, and the plans will be finalised in the next few month...

As a group, Shriram had a "hand-to-mouth" existence when it came to capital, and depended for internal accruals and money from private equi...

Ajay Piramal, who picked up an additional 5.5 percent in Vodafone, described the move "a short-term investment", saying it will cash out wh...

At a time when market is volatile and confusing, Ajay Piramal thinks to buy small stakes in various companies, which are low-risk, generate...

In terms of valuation, Abbott purchase of Piramal's healthcare unit is far ambitious than Daiichi Sankyo’s purchase of Ranbaxy. Full covera...

The Mumbai Metropolitan Region Development Authority (MMRDA) on Tuesday auctioned three plots in city’s Bandra-Kurla Complex (BKC) for Rs 1...

: Domestic pharma major Nicholas Piramal India (NPIL) has decided to invest some Rs 250-300 crore in the next two years in its recently dem...

As the costs of medicines are high abroad, the MNCs need Indian companies to manufacture their products.